Skip to main content

Endosomal Escape

Endosomal Escape for PNA Conjugates

A carrier peptide gets the PNA into the cell. It does not get the PNA out of the compartment it arrives in. Most of a CPP–PNA conjugate taken up by endocytosis stays in endosomes and is eventually degraded, and only the fraction that crosses into the cytosol does anything at all. This is the reason a conjugate that binds its target perfectly can show no effect in cells, and it is a distinct problem from uptake with its own distinct remedies.

A flow showing a CPP-PNA conjugate taken up by endocytosis into an endosome, from which most material stays trapped and is degraded while a small fraction reaches the cytosol and nucleus. Below, two kinds of remedy are compared: adding an escape agent such as chloroquine, calcium ions, high sucrose or photochemical internalization, which works in culture but is described as difficult to envisage in vivo and was reported to reduce cell viability in one study; and engineering the carrier peptide so it escapes unaided, which has been shown both in culture and in mouse muscle.
The two remedies differ less in whether they work than in whether they survive the move out of cell culture.

The evidence that trapping is what limits the experiment

The diagnosis is well established and rests on two observations made together. Uptake of a PNA–oligolysine conjugate was temperature-dependent and led to sequestration of the conjugate in cytoplasmic vesicles, consistent with an endocytic mechanism of internalisation; significant and sequence-specific splicing correction was then achieved only in the presence of endosome-disrupting agents such as chloroquine or 0.5 M sucrose1.

The practical consequence shows up as a concentration requirement. Splicing correction by PNA or morpholino oligomers conjugated to standard carriers such as Tat or penetratin has required 5–10 µM of conjugate unless an endosomolytic agent was added to increase escape from endocytic vesicles2. If your conjugate only works in the micromolar range, endosomal sequestration is the first thing to suspect rather than the binding.

The agents, and what they are good for

Three treatments are used routinely, and protocols for all three — photodynamic treatment (photochemical internalization), Ca2+ treatment and chloroquine treatment — have been published together specifically for potentiating the antisense effect of CPP–PNA conjugates by increasing release into the cytoplasm3. High sucrose is a fourth1.

Photochemical internalization is the most striking of them. Tetramethylrhodamine- and, to a lesser extent, Alexa Fluor 555-conjugated octaarginine PNAs showed more than a ten-fold increase in antisense activity in the HeLa pLuc705 splice correction assay on irradiation, delivering to the cytosol about as effectively as chloroquine-assisted delivery4. It also makes a point worth remembering when choosing a label: the fluorophore on a conjugate is not necessarily inert, and a lipophilic chromophore can change where the construct ends up.

The limitation is not efficacy. It is that the use of such agents in vivo is difficult to envisage2, which means an experiment built on them does not transfer. There is also a tolerability caveat worth knowing before designing around them: one group reported that in their hands the improvements from calcium and chloroquine were relatively small and that the additions reduced cell viability5.

Chloroquineraises endosomal pH; the standard diagnostic for whether trapping is the limit
Calcium ionspromotes endosomal rupture; published as a protocol alongside chloroquine
High sucrose0.5 M has been used to achieve sequence-specific splicing correction
Photochemical internalizationlight plus a photosensitiser or lipophilic dye; the largest reported effect
All fouruseful in culture; not a route to an animal experiment

The remedy that transfers: change the carrier

If adding an agent is the diagnostic, improving the peptide is the fix. Adding six arginines to the N-terminus of penetratin gave a conjugate that produced efficient dose-dependent splice correction in the absence of chloroquine, under conditions where no toxicity was observed2. The same work is honest about the remaining gap: adding chloroquine still improved activity, which shows that some of the conjugate was still entrapped2. Better carriers reduce the problem rather than abolishing it.

The reason this is the right direction is that it survives the move out of culture. A later series of PNA internalisation peptides was tested in animals: injected into the tibialis anterior muscles of mdx mice, the conjugates produced roughly three times as many dystrophin-positive fibres as either the unconjugated PNA or the conjugate carrying the arginine-repeat carrier6. No endosomolytic agent is involved in that result.

A practical sequence

  • Run the experiment with and without chloroquine. If activity rises substantially with it, endosomal trapping is limiting you and the rest of this page applies. If it does not, the problem is elsewhere — uptake, target accessibility or the sequence itself.
  • Check the temperature dependence if you want to confirm the uptake route. Loss of activity at 4 °C points to endocytosis rather than direct translocation.
  • If the work will stay in culture, an escape agent is a legitimate tool, provided the viability controls are run alongside it.
  • If the work is heading towards an animal model, change the carrier peptide instead. Carriers designed for unaided escape exist and have been validated in vivo.
  • Keep the label in mind as a variable. A lipophilic fluorophore is part of the construct's behaviour, not just its readout.

Which carrier to attach in the first place, how the linkage and the peptide's position affect activity, and the published head-to-head comparisons are covered in CPP–PNA conjugate design.

What to send us

Send the PNA sequence, the carrier peptide and which terminus it should sit on, and tell us whether the work will stay in culture or move to an animal model — that distinction changes which carrier is worth using. If you intend to label the conjugate, say so at the quoting stage rather than afterwards, since the label is part of the construct and affects both the synthesis route and the behaviour described above.

We build the peptide and the PNA as a single construct where the chemistry allows, review the combined sequence for solubility before synthesis, and include purification and mass confirmation.

Related reading

References

  1. Abes S, Williams D, Prevot P, Thierry A, Gait MJ, Lebleu B. Endosome trapping limits the efficiency of splicing correction by PNA-oligolysine conjugates. Journal of Controlled Release 2006;110:595–604.
  2. Abes S, Turner JJ, Ivanova GD, Owen D, Williams D, Arzumanov A, Clair P, Gait MJ, Lebleu B. Efficient splicing correction by PNA conjugation to an R6-penetratin delivery peptide. Nucleic Acids Research 2007;35(13):4495–4502. doi:10.1093/nar/gkm418
  3. Shiraishi T, Nielsen PE. Enhanced delivery of cell-penetrating peptide–peptide nucleic acid conjugates by endosomal disruption. Nature Protocols 2006;1:633–636.
  4. Yarani R, Shiraishi T, Nielsen PE. Effective photo-enhancement of cellular activity of fluorophore-octaarginine antisense PNA conjugates correlates with singlet oxygen formation, endosomal escape and chromophore lipophilicity. Scientific Reports 2018;8:638. doi:10.1038/s41598-017-18947-x
  5. Hu J, Corey DR. Inhibiting gene expression with peptide nucleic acid (PNA)–peptide conjugates that target chromosomal DNA. Biochemistry 2007;46(25):7581–7589.
  6. Ivanova GD, Arzumanov A, Abes R, Yin H, Wood MJA, Lebleu B, Gait MJ. Improved cell-penetrating peptide–PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle. Nucleic Acids Research 2008;36(20):6418–6428. doi:10.1093/nar/gkn671

Sequences supplied by customers are treated as confidential and are never disclosed or reused.

All LifeTein products are supplied for laboratory research use only. They are not for human or veterinary use, and not for diagnostic or therapeutic use.